Purpose: This study investigates the effects of 0.05% topical tacrolimus as an adjunct therapy for patients with non-necrotizing herpetic stromal keratitis (HSK).

Methods: Patients with non-necrotizing HSK, referred to the Cornea Clinic at Hospital in Rasht, Iran, between September 2016 and February 2018, were randomly assigned to two groups. The case group ( = 25) and the control group ( = 25) received conventional treatment with systemic acyclovir and topical prednisolone. The case group ( = 25) additionally received 0.05% tacrolimus eye drops four times a day for one month. Complete ocular examinations, including best-corrected visual acuity (BCVA) assessment, intraocular pressure (IOP) measurement, slit lamp biomicroscopy, and photo slit lamp imaging, were performed before treatment, and 3, 7, 14, 21, and 28 days after the intervention.

Results: The mean age of the patients was 46.2 12.9 years, and 70% of the patients were male. There was no difference between the groups in terms of age, sex, and baseline ocular measurements ( 0.05). The case group had a lower mean logarithm of the minimum angle of resolution (LogMAR) for BCVA, lower grading scores, and steeper decreasing trends for corneal haziness, edema, neovascularization, and epitheliopathy compared to the control group after the second week ( 0.05), while IOP remained unchanged between groups ( 0.05).

Conclusion: The addition of 0.05% topical tacrolimus enhances visual acuity and reduces corneal inflammation, neovascularization, and scarring; thus, it can used as an appropriate adjunct treatment for patients with HSK.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825688PMC
http://dx.doi.org/10.18502/jovr.v14i4.5437DOI Listing

Publication Analysis

Top Keywords

topical tacrolimus
12
case group
12
tacrolimus adjunct
8
005% topical
8
patients non-necrotizing
8
control group
8
visual acuity
8
slit lamp
8
patients
5
group
5

Similar Publications

This is the English version of the 2024 clinical practice guidelines for the management of atopic dermatitis (AD). AD is a disease characterized by relapsing eczema with pruritus as a primary lesion. A crucial aspect of AD treatment is the prompt induction of remission via the suppression of existing skin inflammation and pruritus.

View Article and Find Full Text PDF

Efficacy of mycophenolate mofetil combined with topical 0.05% tacrolimus in high-risk keratoplasty: 1-year cohort study.

Int J Ophthalmol

December 2024

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, Guangdong Province, China.

Aim: To investigate the efficacy of systemic mycophenolate mofetil (MMF) as an adjunct in combination with topical tacrolimus (FK506) and corticosteroid eyedrops for preventing corneal graft rejection after high-risk keratoplasty (HRK).

Methods: In this cohort study, 55 consecutive patients (55 eyes) from an eye center who met the criteria of HRK were included. The definition for HRK includes large grafts of no less than 9 mm diameter, vascularized cornea of two or more quadrants, regrafting, or eccentric grafts.

View Article and Find Full Text PDF

Morphea is a chronic inflammatory skin disease characterized by skin fibrosis with variable clinical presentation. We report a case of a young woman who presented with asymptomatic progressive indurated short cords on the neck. A diagnosis of morphea was made based on clinical and histopathological findings.

View Article and Find Full Text PDF
Article Synopsis
  • - Pigmentary disorders like Lichen planus pigmentosus (LPP) and vitiligo can lead to significant cosmetic concerns and psychosocial stress for patients.
  • - A 61-year-old man with LPP developed vitiligo and was successfully treated with low-dose isotretinoin and topical tacrolimus ointment.
  • - The coexistence of LPP and vitiligo might be explained by an autoimmune process affecting skin pigmentation called melanocytorrhagy.
View Article and Find Full Text PDF
Article Synopsis
  • - Oral lichen planus (OLP) is a chronic inflammatory autoimmune condition affecting the mouth, often leading to decreased quality of life and potential cancer risks; traditional treatment primarily involves topical corticosteroids, which have undesirable side effects.
  • - Interest is growing in alternative treatments, particularly topical calcineurin inhibitors (TCIs) like tacrolimus, which provide a steroid-sparing option and aim for localized effectiveness with less systemic absorption.
  • - The management of OLP is complex and requires various treatment strategies; ongoing research is focused on developing safer, more effective therapies, including innovative drug delivery systems and biologics, to improve patient outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!